Emily is a Scientist managing In Vivo Operations the at the Gene Editing Institute, contributing as part of the research team in pursuit of their pre-Investigational New Drug targets using her combination of in vivo and in vitro experience. She completed her M.S. at Drexel College of Medicine for Drug Discovery & Development in December of 2022. Prior to coming to the Gene Editing Institute, Emily's focus was in Developmental and Reproductive Toxicology (DART) safety assessment studies at Charles River Laboratories with a strong focus in data QC and advanced animal model dosing and specimen collection techniques. Additionally, during her time as a Fellow through Maryland Sea Grant, she focused her work on the biogeography of sulfide oxidizing bacteria in tidal sub-estuaries using various bacterial enumeration techniques. Emily continues to maintain a strong focus on animal model use in research studies.
